Trump’s Back, but DC’s Coming for Your Money!

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

Calvin Yu Biography and Net Worth

VP of Alector

Calvin has led our Finance team since June 2017. Calvin joined Alector from biotechnology company Stemcentrx, Inc. (acquired by AbbVie), where he served as Corporate Controller from February 2016 to June 2017. Prior to Stemcentrx, Calvin held several senior level finance role at publicly traded biotechnology companies, including Senior Director of Finance and SEC Reporting at Adverum Biotechnologies, Inc. from September 2014 to February 2016, and Controller at Five Prime Therapeutics, Inc. from March 2010 to September 2014. Calvin holds a B.S. in Accounting from San Francisco State University, College of Business.

What is Calvin Yu's net worth?: The estimated net worth of Calvin Yu is at least $622,028.26 as of June 2nd, 2021. Mr. Yu owns 126,686 shares of Alector stock worth more than $622,028 as of November 14th. This net worth approximation does not reflect any other investments that Mr. Yu may own. Learn More about Calvin Yu's net worth.
How do I contact Calvin Yu?: The corporate mailing address for Mr. Yu and other Alector executives is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. Alector can also be reached via phone at (415) 231-5660 and via email at [email protected]. Learn More on Calvin Yu's contact information.
Has Calvin Yu been buying or selling shares of Alector?: Calvin Yu has not been actively trading shares of Alector during the last ninety days. Most recently, Calvin Yu sold 3,334 shares of the business's stock in a transaction on Tuesday, July 6th. The shares were sold at an average price of $34.65, for a transaction totalling $115,523.10. Learn More on Calvin Yu's trading history.
Who are Alector's active insiders?: Alector's insider roster includes Robert King (Insider), Robert Paul (Insider), Arnon Rosenthal (CEO), Richard Scheller (Director), Shehnaaz Suliman (COO), and Calvin Yu (VP). Learn More on Alector's active insiders.
Are insiders buying or selling shares of Alector?: During the last year, insiders at the sold shares 13 times. They sold a total of 162,311 shares worth more than $875,829.44. The most recent insider tranaction occured on September, 3rd when CFO Marc Grasso sold 7,297 shares worth more than $35,609.36. Insiders at Alector own 9.1% of the company. Learn More about insider trades at Alector.
Information on this page was last updated on 9/3/2024.

Calvin Yu Insider Trading History at Alector

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2021	Sell	3,334	$34.65	$115,523.10
7/2/2021	Sell	110,840	$32.74	$3,628,901.60
6/2/2021	Sell	1,844	$17.77	$32,767.88	126,686
6/3/2020	Sell	1,343	$31.26	$41,982.18	110,986
2/4/2020	Sell	63,541	$30.04	$1,908,771.64	188,835
12/3/2019	Sell	1,315	$19.39	$25,497.85

Calvin Yu Buying and Selling Activity at Alector

Alector Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $4.91

$4.89

$5.16

50 Day Range

MA: $5.11

$4.22

$6.14

2 Week Range

Now: $4.91

$3.66

$8.90

Volume

433,018 shs

Average Volume

621,760 shs

Market Capitalization

$480.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66